Erratum: Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma) (Melanoma Research (1999) 9, (503-509))

M. R. Sertoli, P. Queirolo, E. Bajetta, M. Del Vecchio, G. Comella, L. Barduagni

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)340
Number of pages1
JournalMelanoma Research
Issue number5
Publication statusPublished - Oct 2007

ASJC Scopus subject areas

  • Cancer Research
  • Dermatology

Cite this